Company: Enbodie
CEO & Founders: Darren Crowder & Niki Patel
Website: https://www.enbodie.me
About Enbodie
Enbodie is a purpose-focused healthtech platform pioneering hyper-personalised, preventative AI-driven dermatology by combining ethnicity-aware multi-agent AI with clinically validated toxicology and real-world data to empower individuals and enterprises to make safer, more effective choices about skin health and wellness.
Leveraging 3.9 billion smartphones globally, we democratise clinical-grade dermatological insights through ubiquitous smart devices, transforming every mobile phone into a personal health diagnostic tool accessible to billions worldwide. This approach addresses healthcare accessibility challenges whilst maintaining clinical rigour, similar to how DERM technology is being implemented in NHS pathways.
The consumer data generated across these billions of devices represents unprecedented value for advancing global health outcomes. We bring this multitude of user data together securely with explicit user consent into our secure central Data as a Service platform. Before any data leaves the smart device, all personally identifiable information is removed, images are moved to secure blockchain storage, and all data is anonymised before DaaS integration. This privacy-first approach enables enterprises to derive actionable insights whilst protecting individual privacy.
Having ethnicity data combined with product ingredient information allows manufacturers like L’Oréal, P&G, and Unilever to develop safer R&D approaches by understanding how different ingredients affect various ethnic skin types, enabling targeted reformulation that reduces adverse reactions across diverse populations. Our ethnicity and gender data supports inherently safer product development by identifying ingredient combinations causing differential responses across demographic groups, allowing proactive safety measures rather than reactive recalls.
Our supply chain and ESG consumer usage data enables organisations to reduce the 120 billion units of single-use packaging in the beauty industry by identifying consumer behaviour patterns, preferred sustainable alternatives, and packaging preferences that inform circular economy initiatives.
Founded in London to overcome fragmented clinical skin health guidance, Enbodie develops advanced AI algorithms processing over 45 million toxicology data points and one million user images. Our platform delivers instant, hyper-personalised recommendations via selfie analysis, biomarker integration, wearables connectivity and ingredient assessment, bridging critical gaps in safety, equity and transparency for diverse global populations.
Clinical validation through our several hundred user trial demonstrated significant behavioural modification, achieving 3.4 SKU changes per user towards safer alternatives whilst generating £60 monthly savings per participant. Over 80 per cent improved sustainability scores, proving measurable health and environmental outcomes whilst feeding our proprietary data flywheel.
Commercial success includes pre-revenue customers and strategic partnerships with Radiant-Cersei/Digital Health London for Software (SaMD) and AI as Medical Device (AIaMD) regulatory strategy, NVIDIA Inception Programme and Microsoft for Startups. Built on Microsoft Azure with GDPR, SOC 2, HIPAA and HL7 compliance, blockchain-secured architecture ensures global scalability and clinical-grade data security. We achieved 84 per cent pre-approved pass rate for 16 UK patent filings and recognition amongst Top 60 TechRound sustainability companies.
Future capabilities target comprehensive preventative health beyond dermatology, encompassing GP-level primary care through specialist consultant referrals via AI-powered triage at the edge with human-in-the-loop validation. Our smart device infrastructure enables seamless healthcare continuum integration, facilitating early detection and intervention before conditions require costly treatment.
From Science to Self-Care, Enbodie bridges clinical innovation and everyday wellness by democratising expert-level health guidance, driving evidence-based product development and empowering informed health decisions through preventative intervention rather than reactive treatment approaches.
